


SUPPLEMENTARY FIGURES




Supplementary Figure 1. The protein-protein interaction network analysis. (A) The protein-protein interaction network analysis between the 18 m⁶A regulators and the other proteins. (B) The protein-protein interaction network analysis between these three selected m⁶A RNA methylation regulators and the other proteins.




Supplementary Figure 2. Genetic changes of RNA m⁶A regulators in the TCGA dataset. Genetic changes of the 18 m⁶A RNA methylation regulators in the 379 OC from the TCGA dataset.




Supplementary Figure 3. Identification of consensus clusters by m^6A RNA methylation regulators and PCA. (A) Comparative change in area under cumulative distribution function (CDF) curve for k = 2 to 10. (B) Consensus clustering CDF for k = 2 to 10. (C) PCA of the total RNA expression profile.




Supplementary Figure 4. OS of OC patients with different tumor grades. Kaplan-Meier OS curves for patients in the TCGA datasets depended on grade.




Supplementary Figure 5. Heatmap of the 18 m⁶A RNA methylation regulators. Heatmap and clinicopathologic features of the two clusters (high risk and low risk) defined by the 18 m⁶A RNA methylation regulators' risk score.



Supplementary Figure 6. Expression of IGF2BP1, VIRMA and ZC3H13 in OC patients with different types, ages and grades. (A) Expression of IGF2BP1 in different ovarian cancer in the Oncomine database. (B) Expression of VIRMA in different ovarian cancer in the Oncomine database. (C) Expression of IGF2BP1 in OV based on the patient's age. (E) Expression of VIRMA in OV based on patient's age. (F) Expression of ZC3H13 in OV based on the patient's age. (G) Expression of IGF2BP1 in OV based on tumor grade. (H) Expression of VIRMA in OV based on tumor grade. (I) Expression of ZC3H13 in OV based on tumor grade. OV: Ovarian serous cystadenocarcinoma



Supplementary Figure 7. Mutation data of three selected m⁶A RNA methylation regulators in different OC cell lines based on the Cancer Cell Line Encyclopedia (CCLE) database. (A) Mutation sites of VIRMA in different OC cell lines. (B) Mutation sites of ZC3H13 in different OC cell lines. (C) Mutation sites of IGF2BP1 in different OC cell lines.



Supplementary Figure 8. Protein expression of IGF2BP1, VIRMA and ZC3H13 in OC patients in the CPTAC samples. (A) Protein expression of IGF2BP1in OC patients. (B) Protein expression of VIRMA in OC patients. (C) Protein expression of ZC3H13 in OC patients.